Frontiers in Oncology (Mar 2022)

Expression Patterns of Ezrin and AJAP1 and Clinical Significance in Breast Cancer

  • Cong Xu,
  • Feng Wang,
  • Li Hao,
  • Jing Liu,
  • Jing Liu,
  • Jing Liu,
  • Benjie Shan,
  • Shuhua Lv,
  • Xinghua Han,
  • Yueyin Pan,
  • Yun Niu,
  • Yun Niu,
  • Yun Niu

DOI
https://doi.org/10.3389/fonc.2022.831507
Journal volume & issue
Vol. 12

Abstract

Read online

Ezrin and adherens junction-associated protein 1 (AJAP1) are structural proteins which are involved in numerous human malignancies. However, little is known about the relationship between them in breast cancer. This study was set out to investigate the relationship between them and to further explore the mechanism of AJAP1-mediating cytoskeleton in breast cancer progression. Ezrin and AJAP1 expressions were detected in 377 samples of breast cancer by immunohistochemistry, and different expression patterns between AJAP1 and Ezrin with clinicopathological parameters were analyzed. Besides, univariate and multivariate Cox models were used to evaluate their prognostic potential. Enzyme-linked immunosorbent assay, Western blot, qRT-PCR, and phalloidin staining of F-actin were used to explore the relationship and the mechanism between AJAP1 and Ezrin in cytoskeleton arrangement. 377 cases of breast cancer results showed that AJAP1 expression was negatively related with histological grade and lymph node involvement and could be an independent prognosis marker of breast cancer. AJAP1 expression tended to be higher in the Ezrin-negative expression case. Patients with AJAP1negative and Ezrinpositive expression had a worse prognosis (p < 0.0001) and shorter DFS (p = 0.015). More importantly, AJAP1 depletion increased the cell ability of F-actin formation through promoting Ezrin expression. AJAP1 depletion might mediate breast cancer malignancy potential through promoting Ezrin expression and cytoskeleton formation.

Keywords